University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity medications compared to lifestyle modification alone. Results indicate that ...

Fortunately, with President Trump’s leadership on the issue, he can turn the tide in the quest to end obesity. There’s a ...

While weight-loss drugs like Zepbound (LLY) and Wegovy (NVO) offer significant health benefits, their high costs make them ...

A coalition of industry organizations is pressing employers to offer coverage for obesity as they would for other chronic ...

The Canadian Medical Association and the World Health Organization (WHO) consider obesity as a progressive chronic disease ...

One effective action involves addressing obesity, a major driver of chronic disease and health care costs. Obesity is an ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Despite substantial health benefits, two GLP-1 receptor agonists weren't cost-effective at their current prices, according to ...

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

But the letter from the health-care alliance said employers spend about $425.5 billion annually on health-care costs ...